Last $23.27 USD
Change Today +0.18 / 0.78%
Volume 131.6K
As of 8:04 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

cambrex corp (CBM) Snapshot

Open
$23.12
Previous Close
$23.09
Day High
$23.49
Day Low
$23.08
52 Week High
11/13/14 - $24.14
52 Week Low
01/27/14 - $15.20
Market Cap
721.3M
Average Volume 10 Days
173.2K
EPS TTM
$0.90
Shares Outstanding
31.0M
EX-Date
05/4/07
P/E TM
25.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for CAMBREX CORP (CBM)

cambrex corp (CBM) Related Bloomberg News

View More Bloomberg News

cambrex corp (CBM) Related Businessweek News

No Related Businessweek News Found

cambrex corp (CBM) Details

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products consist of active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products. The company serves generic drug companies, and companies that discover and commercialize new small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

936 Employees
Last Reported Date: 02/11/14
Founded in 1981

cambrex corp (CBM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $533.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $400.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $412.5K
Managing Director of Cambrex Profarmaco Milan...
Total Annual Compensation: $338.7K
Compensation as of Fiscal Year 2013.

cambrex corp (CBM) Key Developments

Cambrex Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for the Full Year 2014

Cambrex Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $80,641,000 compared to $77,445,000 a year ago. Net revenues were $81,300,000 compared to $77,452,000 a year ago. Operating profit was $12,026,000 compared to $11,250,000 a year ago. The increase in operating profit was primarily the result of higher gross profit partially offset by higher operating expenses. Income before income taxes was $11,419,000 compared to $10,073,000 a year ago. Income from continuing operations was $8,882,000 or $0.28 per diluted share compared to $6,274,000 or $0.20 per diluted share a year ago. Net income was $8,769,000 or $0.28 per diluted share compared to $3,574,000 or $0.12 per diluted share a year ago. EBITDA was $18,092,000 compared to $16,995,000 a year ago. Adjusted income from continuing operations was $8,849,000 or $0.28 per diluted share compared to $7,117,000 or $0.23 per diluted share a year ago. Capital expenditures were $7.2 million. For the nine months, the company reported net sales of $243,631,000 compared to $213,426,000 a year ago. Net revenues were $245,298,000 compared to $215,140,000 a year ago. Operating profit was $29,720,000 compared to $33,245,000 a year ago. Income before income taxes was $23,451,000 compared to $29,930,000 a year ago. Income from continuing operations was $29,875,000 or $0.95 per diluted share compared to $20,835,000 or $0.67 per diluted share a year ago. Net income was $29,418,000 or $0.93 per diluted share compared to $17,016,000 or $0.55 per diluted share a year ago. Adjusted operating profit was $29,720,000 compared to $28,565,000 a year ago. Adjusted EBITDA was $47,635,000 compared to $45,196,000 a year ago. Adjusted income from continuing operations was $21,774,000 or $0.69 per diluted share compared to $19,204,000 or $0.62 per diluted share a year ago. The company continues to expect full year 2014 sales, excluding the impact of foreign currency, to grow between 13% and 16% from 2013, and adjusted EBITDA to be between $74 and $78 million. Adjusted income from continuing operations is now expected to be between $1.11 and $1.19 per share compared to previous guidance of $1.07 to $1.15. The company expects capital expenditures of $35 million to $39 million, depreciation of $24 million to $25 million compared to previous guidance of $25 million to $27 million and effective tax rate of 33% to 36%.

Cambrex Corporation. to Report Q3, 2014 Results on Oct 30, 2014

Cambrex Corporation. announced that they will report Q3, 2014 results at 8:30 AM, US Eastern Standard Time on Oct 30, 2014

Cambrex Corporation., Q3 2014 Earnings Call, Oct 30, 2014

Cambrex Corporation., Q3 2014 Earnings Call, Oct 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBM:US $23.27 USD +0.18

CBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aceto Corp $21.51 USD +0.24
Albany Molecular Research Inc $15.50 USD -0.29
Biocon Ltd 460.10 INR -2.50
Produits Chimiques Auxiliaires et de Synthese €3.71 EUR +0.03
Siegfried Holding AG SFr.153.10 CHF -0.80
View Industry Companies
 

Industry Analysis

CBM

Industry Average

Valuation CBM Industry Range
Price/Earnings 18.4x
Price/Sales 2.0x
Price/Book 3.1x
Price/Cash Flow 18.7x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CAMBREX CORP, please visit www.cambrex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.